Aethlon Medical Inc (AEMD)

[Tahoe2468]

The Hunt for Virus Treatments Continues Post Covid-19
Newsfile - Fri Jun 7, 7:16AM CDT Contributor Content

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 7, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of viruses, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Read the full article on Investorideas.com
https://www.investorideas.com/News/2024/biotech/06070Virus-Treatments-Post-Covid-19.asp

The threat of viruses is back in the news with multiple news sources, including the Guardian reporting, "The World Health Organization (WHO) has said a man's death in Mexico was caused by a strain of bird flu called H5N2 that has never before been found in a human."

The WHO said Wednesday it wasn't clear how the person became infected. "Although the source of exposure to the virus in this case is currently unknown, A (H5N2) viruses have been reported in poultry in Mexico," it said in a statement.

Continued: "Scientists are on alert for changes in the virus that could signal that bird flu is adapting to spread more easily among humans.

Continued: "But the UN agency said Wednesday said the current risk of the bird flu virus to the general population in Mexico is low."

With global populations and economies still feeling the impact of Covid-19, any virus threat is going to make headlines.

As viruses make headlines, companies are seeking solutions and not all are focused on vaccine development.

Aethlon Medical, Inc. (NASDAQ: AEMD) just recently announced an update on its technology for cancer treatment on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

The Aethlon Hemopurifier® technology is designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a "Breakthrough Device" for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and life-threatening viruses that are not addressed with approved therapies.

As reported previously, separate from its current focus on cancer treatment, Aethlon has investigated the potential for the use of the Hemopurifier® in viral diseases.

According to their SEC filing, "We also believe the Hemopurifier can be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola."

"Additionally, in vitro, the Hemopurifier has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research institutes."

Recently, Zacks reported that "Vaccine Stocks Rise on Growing Threat of Bird Flu Infections."

"Shares of several vaccine makers soared after reports suggest that the Biden administration is in discussions with Moderna and Pfizer to set up a possible vaccine program aimed at preventing the spread of the H5N1 virus, also known as bird flu, in humans."

Continued: "These reports came to light after the discovery of two cases of H5N1 virus in dairy farm workers in Texas and Michigan this year. Both these workers experienced symptoms in the eye after coming into contact with dairy cows infected with the H5N1 virus."

But the treatment of viral diseases has other options including immunotherapy.

ImmunityBio, a clinical-stage immunotherapy company, announced earlier this year the publication of preclinical data in the online issue of Science, First Release indicating that combination therapy with N-803, an IL-15 superagonist, and broadly neutralizing antibodies may potentially enable the immune system to manage human immunodeficiency virus (HIV) without the need for antiretroviral treatment.